17. July 2026

Colorectal Cancer Prevention: AI Does Not Automatically Lead to Better Outcomes Colorectal Cancer Prevention: AI Does Not Automatically Lead to Better Outcomes

International Lancet Study Led by Researchers in Bonn Examines the Use of AI in People at High Risk for Colorectal Cancer

People with Lynch syndrome, the most common hereditary predisposition to colorectal cancer, are at a significantly increased risk of developing colorectal cancer. Many affected individuals therefore undergo a colonoscopy every one to two years, starting in young adulthood. Researchers from the University Hospital Bonn (UKB) and the University of Bonn, in collaboration with the University of Leipzig and Amsterdam UMC, investigated whether artificial intelligence (AI) can improve the detection of precancerous lesions in these high-risk patients. The result: In specialized centers, the additional AI support did not provide any significant benefit. The findings have now been published in the journal The Lancet Gastroenterology & Hepatology.

Dr. Robert Hüneburg (left) and Prof. Dr. Jacob Nattermann
Dr. Robert Hüneburg (left) and Prof. Dr. Jacob Nattermann - of the University Hospital Bonn (UKB) investigated whether artificial intelligence can improve colorectal cancer screening in people with Lynch syndrome. Their study shows that, in specialized centers, the expertise of experienced endoscopists remains the decisive factor in detecting precancerous lesions. © University Hospital Bonn (UKB) / Aljoscha Mismas
Download all images in original size The impression in connection with the service is free, while the image specified author is mentioned.
Please fill out this field using the example format provided in the placeholder.
The phone number will be handled in accordance with GDPR.

Lynch syndrome affects an estimated one in 300 people, making it the most common hereditary cause of colorectal cancer. Despite regular surveillance colonoscopies, the lifetime risk of colorectal cancer for many affected individuals remains around 50 percent. This makes the highest possible quality of colonoscopy all the more important.

“People with Lynch syndrome often undergo regular colonoscopies over the course of decades. For them, any improvement in surveillance is of great importance,” says co-first author Dr. Robert Hüneburg, senior physician at Medical Clinic I of the UKB, which is part of the Center for Integrated Oncology (CIO) in Bonn. “That’s why we wanted to know whether artificial intelligence could make an additional contribution to detecting precancerous lesions even more reliably.”

Largest Study of Its Kind

For the international CADLY2 study, 757 people with genetically confirmed Lynch syndrome were examined at nine specialized centers in Germany, the Netherlands, Spain, and Belgium. The researchers investigated whether an AI-supported assistance system detects more adenomas during colonoscopy than a high-quality standard colonoscopy without AI support. These changes in the intestinal mucosa are considered important precursors to colorectal cancer, and their early removal can prevent the development of cancer.

This makes CADLY2 the largest endoscopic study to date worldwide involving people with Lynch syndrome and, at the same time, the largest randomized trial on the use of artificial intelligence in this high-risk group. The study was initiated and coordinated at the University Hospital Bonn, which also recruited a significant proportion of the patients included in the study.

Experience Remains Crucial

The analysis showed that, in specialized centers, additional AI support did not lead to the detection of more relevant precancerous lesions compared with standard colonoscopy performed by experienced examiners. The high quality of the examinations left little room for further improvements through the technology used.

“The result may seem surprising at first,” says co-senior author Prof. Dr. Jacob Nattermann, head of the Hepatogastroenterology Section at Medical Clinic I of the UKB and a member of the Transdisciplinary Research Area (TRA) “Life & Health” at the University of Bonn. “Our findings show that modern AI systems do not automatically lead to better outcomes. In specialized centers with a high level of expertise, careful colonoscopy performed by experienced examiners remains the decisive factor in cancer prevention.”

According to the researchers, the results do not fundamentally rule out the use of artificial intelligence in endoscopy. Rather, they show that the benefits of new technologies depend heavily on the clinical setting, the examiners’ experience, and the initial quality of the examination.

“Our study helps to realistically assess the use of artificial intelligence in high-risk surveillance,” said Dr. Hüneburg. “At the same time, the results underscore the importance of specialized centers and structured surveillance programs for people with Lynch syndrome.”

“The study makes an important contribution to the evidence-based assessment of artificial intelligence in colorectal cancer surveillance,” emphasizes Prof. Dr. Christian P. Strassburg, Director of Medical Clinic I and author of the study. Future studies will now investigate in which areas and under what conditions AI systems can actually provide additional benefits for patients.

In addition to the University Hospital Bonn and the University of Bonn, participants included the Institute for Medical Informatics, Statistics, and Epidemiology (IMISE) at the University of Leipzig, Amsterdam UMC, and other specialized centers in Germany, the Netherlands, Spain, and Belgium.

Robert Hüneburg et al., “CADLY2: Artificial intelligence-assisted adenoma detection in patients with Lynch syndrome undergoing colonoscopy – an international multicentre randomised controlled trial”, in The Lancet Gastroenterology & Hepatology, 2026. DOI: https://doi.org/10.1016/S2468-1253(26)00163-9

Dr. Robert Hüneburg
Senior Physician at Medical Clinic I
University Hospital Bonn
E-Mail: robert.hueneburg@ukbonn.de  

Wird geladen